News

Stocktwits on MSN1d
Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels
Denmark-headquartered Novo Nordisk (NVO) has entered into a collaboration and exclusive worldwide license agreement with ...
Pharmaceutical Technology on MSN1d
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...
Contract Pharma1d
Novo Nordisk Signs $800M+ Deal with Deep Apple Therapeutics for Obesity R&D
Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with ...
Fierce Biotech2d
Novo Nordisk finds Deep Apple ripe for obesity R&D, inking $812M deal to go beyond incretins
Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...
Novo Nordisk Signs $812 Million Obesity Drug Development Deal With Deep Apple
Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.
Medical Dialogues1d
Novo Nordisk, Deep Apple Therapeutics ink pact to develop oral therapeutics for Cardiometabolic Diseases
Deep Apple Therapeutics, Inc. has announced a research collaboration and exclusive worldwide license agreement with Novo ...